

Medical Policy
Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea

Document Number: 051

	Commercial and Qualified Health Plans	MassHealth
Authorization required	X	
No Prior Authorization		
Not covered		X

Overview

The purpose of this document is to describe the guidelines AllWays Health Partners utilizes to determine medical necessity for implantation of an FDA approved hypoglossal nerve stimulation (HGNS) device, for obstructive sleep apnea (OSA).

Coverage Guidelines

AllWays Health Partners covers implantation of an FDA approved hypoglossal nerve stimulator device for obstructive sleep apnea in members when ALL the following are met:

- The member is 22 years of age or older with a diagnosis of obstructive sleep apnea; and
- The member’s apnea hypopnea index (AHI) is greater than or equal to 15 with predominantly obstructive events (defined as central and mixed apneas less than 25% of the total AHI); and
- There is absence of complete concentric collapse at the soft palate level as seen on a drug-induced sleep endoscopy procedure; and
- The member’s body mass index (BMI) is less than 32 kg/m²; and
- There is documentation by a Board-Certified Sleep Medicine Specialist of continuous positive airway pressure (CPAP) trial and failure or intolerance (defined as use less than 4 hours per night, five nights per week).

Exclusions

- When the member does not meet the coverage criteria;
- The device is not an FDA-approved hypoglossal nerve stimulation system

Definitions

Hypoglossal nerve stimulation (HGNS): HGNS, also known as upper airway stimulation, is a treatment that works by stimulating the hypoglossal nerve to restore tone to (or stiffen) the key tongue muscles that when relaxed, can block the airway causing obstruction that reduces or stops breathing during the night. The implantable pulse generator (and battery) is implanted into the chest, the respiratory sensor is implanted in the ribcage, and the stimulation cuff is implanted in the neck around the hypoglossal nerve. The sensing lead and stimulation lead wires are then tunneled to the chest incision and connected to the implantable pulse generator. The fully implanted system is then controlled with the use of a remote.

Obstructive Sleep Apnea: OSA is characterized by recurrent, functional collapse of the upper airway during sleep, causing substantially reduced or complete cessation of airflow despite ongoing respiratory effort. This leads to episodic hypoxemia and fragmented sleep due to arousals. When untreated, these

399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org



result in short term quality of life impairment, such as excessive daytime sleepiness, and increased long term cardiovascular and neurocognitive morbidity and mortality.

CPT/HCPC Codes

Authorized Codes	Code Description
64568	Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator
0466T	Insertion of chest wall respiratory sensor electrode or electrode array, including connection to pulse generator
0467T	Revision or replacement of chest wall respiratory sensor electrode or electrode array, including connection to existing pulse generator
0468T	Removal of chest wall respiratory sensor electrode or electrode array

Effective

January 2020: Effective Date

References

American Academy of Otolaryngology-Head and Neck Surgery. Position Statement: Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea (OSA). 2016; <http://www.entnet.org/content/position-statement-hypoglossal-nerve-stimulation-treatment-obstructive-sleep-apnea-osa>. Accessed August 28, 2018

Barbé F, Masa JF. Hypoglossal neurostimulation for obstructive sleep apnoea. *Eur Respir J*. 2013 Feb;41(2):257-8. doi: 10.1183/09031936.00132312. PubMed PMID: 23370799.

Certal VF, Zaghi S, Riaz M, et al. Hypoglossal nerve stimulation in the treatment of obstructive sleep apnea: A systematic review and meta-analysis. *Laryngoscope*. May 2015;125(5):1254-1264. PMID 25389029

Eastwood PR, Barnes M, Walsh JH, et al. Treating obstructive sleep apnea with hypoglossal nerve stimulation. *Sleep* 2011;34:1479-86. PMID: 22043118

Goding GS, Wondimeneh T, Kezirian EJ, et al. Hypoglossal nerve stimulation and airway changes under fluoroscopy. *Otolaryngol Head Neck Surg* 2012; 146:1017-22. PMID: 22307575

Hayes, Inc. Health Technology Assessment. Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea. Published October 30, 2018. Accessed November 1, 2019

Hong SO, Chen YF, Jung J, Kwon YD, Liu SYC. Hypoglossal nerve stimulation for treatment of obstructive sleep apnea (OSA): a primer for oral and maxillofacial surgeons. *Maxillofac Plast Reconstr Surg*. 2017;39(1):27. Published 2017 Sep 25. doi:10.1186/s40902-017-0126-0

Kezirian EJ, Goding GS, Jr., Malhotra A, et al. Hypoglossal nerve stimulation improves obstructive sleep apnea: 12-month outcomes. *J Sleep Res*. Feb 2014;23(1):77-83. PMID 24033656



Schwartz, AR, Barnes M, Hillman D, et al. Acute upper airway responses to hypoglossal nerve stimulation during sleep in obstructive sleep apnea. *Am J Respir Crit Care Med* 2012; 185; 4:420-6. PMID: 22135343.

Strollo PJ, Jr., Soose RJ, Maurer JT, et al. Upper-airway stimulation for obstructive sleep apnea. *N Engl J Med*. Jan 9 2014;370(2):139-149. PMID 24401051

U.S. Food and Drug Administration (FDA), Center for Devices and Radiologic Health (CDRH). Inspire Upper Airway Stimulation (UAS) System, Model 3028 IPG. Summary of Safety and Effectiveness Data. PMA No. P130008/S021. Rockville, MD: FDA; June 23, 2017. Available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130008S021> Accessed November 1, 2019